You are here: Industry Insights > Merck

News List

Merck Manuals Shares What Parents Need to Know About Adolescent Prediabetes prnewswire
October 30, 2020
Nearly one in five adolescents are living with prediabetes. Prediabetes is a critical warning sign in children at risk of developing type 2 diabetes.
US FDA approves KEYTRUDA from Merck for adults with relapsed or refractory cHL expresspharma
October 16, 2020
KEYTRUDA is the first anti-PD-1 therapy approved for adult patients with relapsed or refractory cHL after frontline therapy.
Moderna regains RSV vaccine programme from Merck pharmaceutical-technology
October 12, 2020
Merck (MSD) has returned all rights to a respiratory syncytial virus (RSV) vaccine, mRNA-1172, to Moderna, including rights to develop vaccines against the virus for adults.
Merck KGaA out-licenses osteoarthritis programme to Novartis pharmatimes
October 10, 2020
Germany’s Merck KGaA has entered into an out-licensing agreement with Novartis for the development of an osteoarthritis clinical-stage programme.
Merck restructures its Executive Board expresspharma
October 10, 2020
Belén Garijo will take charge as Chair of the Executive Board of Merck from Stefan Oschmann in 2021.
Merck’s Keytruda plus chemotherapy meets OS and PFS goals in KEYNOTE-590 trial pharmaceutical-business-review
September 27, 2020
Merck announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of patients ...
Keytruda/Lenvima combo shows promise in hard-to-treat cancers pharmatimes
September 22, 2020
MSD (Merck) and Eisai have revealed new data from two trials under the LEAP clinical programme evaluating the combination of MSD’s PD-1 inhibitor Keytruda and Eisai’s oral tyrosine kinase inhibitor Lenvima.
Vaccinex, Merck Collaborate on Keytruda Combo contractpharma
September 18, 2020
Vaccinex Inc., a clinical-stage biotechnology company, has entered into a clinical collaboration agreement with Merck through a subsidiary, to evaluate the combination of Vaccinex’s investigational SEMA4D inhibitor, pepinemab, and Merck’s anti-PD-1 ...
NKMax America Partners with Merck KGaA and Pfizer contractpharma
September 18, 2020
Will evaluate the safety and tolerability of SNK01 in combination with avelumab (BAVENCIO).
Merck to acquire $1bn equity stake in Seattle Genetics pharmaceutical-technology
September 16, 2020
Drugmaker Merck is acquiring a $1bn equity stake in Seattle Genetics as part of oncology collaborations with the company.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page